Pituitary Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The pituitary cancer market size is projected to expand from USD 0.97 billion in 2025 and USD 1.06 billion in 2026 to USD 1.65 billion by 2031, registering a CAGR of 9.21% between 2026 to 2031. This report is Segmented by Offering (Diagnosis [Magnetic Resonance Imaging and More], Treatment [Surgery and More]), Cancer Type (Functioning Pituitary Adenoma and More), Age Group (Pediatric, Adult, Older Adult), End User (Hospitals, Specialty Clinics, Cancer Treatment Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts are Provided in Terms of Value (USD).

Global Pituitary Cancer Market Trends and Insights

Oral and Long-Acting Formulations Improving Treatment Persistence

The September 2025 FDA approval of paltusotine marked a change in acromegaly treatment because it was the first once-daily oral SST2 agonist for adults. The medicine offers an alternative to monthly intramuscular or subcutaneous injections, which some patients had discontinued. Two-year open-label data from PATHFNDR-1 and PATHFNDR-2, presented in 2026, reported mean IGF-1 levels of 0.81× the upper limit of normal in patients previously using injectables. The untreated group showed a progressive decline toward 0.96× the upper limit of normal, while tumor volume remained stable or declined in the pooled cohort. The Pituitary cancer market benefits when treatment persistence improves because patients can remain on hormone-control therapy for longer periods.

The availability of oral and self-administered options can reduce the number of clinical encounters needed to provide treatment. This shifts part of treatment delivery from hospital outpatient units toward specialty pharmacies. Pharmaceutical manufacturers and specialty pharmacy networks may capture a larger share of recurring treatment activity under this model. Hospitals remain essential for surgery, complex disease, and acute care, but their role in routine drug administration may decline. The Pituitary cancer market therefore gains a more flexible treatment channel without removing the need for specialized supervision.

Rising Detection of Previously Undiagnosed Pituitary Tumors

Pituitary incidentalomas are increasingly identified when brain MRI is ordered for headache, trauma, or cognitive symptoms. Radiographic and autopsy studies have reported pituitary tumors in 10-25% of cases, whereas the number of diagnosed and treated cases remains much lower. This difference shows that many tumors have not yet entered an active management pathway. The Pituitary cancer market can therefore gain volume as more lesions are identified and clinically assessed. The relationship between biological prevalence and treated incidence remains important because not every incidental finding requires intervention.

A detected lesion generally leads to an endocrine assessment rather than an imaging encounter alone. Testing can include IGF-1, prolactin, ACTH stimulation, and broader pituitary function panels. This creates diagnostic activity before a decision on surgery or drug treatment is made. Non-functioning PitNETs are frequently identified through incidental imaging, and endoscopic endonasal surgery is used as a first-line approach in appropriate cases. The Pituitary cancer market gains demand across imaging, laboratory testing, specialist consultations, and treatment planning as detection becomes more common.

Extreme Rarity of Pituitary Carcinoma Limiting Clinical Trial Recruitment

Pituitary carcinoma has an estimated prevalence of 1 per 1,000,000 people and represents fewer than 0.01% of anterior pituitary tumors. It is defined by craniospinal or systemic metastasis, which can appear 5-7.5 years after the initial tumor detection. This low incidence makes prospective randomized trials difficult to conduct at individual institutions. A 2024 review found that fewer than 300 cases had been described globally across 3 decades. The Pituitary cancer market has limited trial throughput for carcinoma-specific treatments because the available patient pool is exceptionally small.

The limited evidence base can discourage development of a carcinoma-specific label. Patients may instead receive temozolomide off label or experimental PRRT where appropriate. This restricts the evidence available for regulatory expansion and premium pricing in late-line therapy. Multi-center registries and consistent pathology reporting would improve the available clinical evidence over time. The Pituitary cancer market remains constrained in this area because the clinical evidence needed for targeted approvals develops slowly.

Other drivers and restraints analyzed in the detailed report include:

• Greater Use of High-Resolution MRI and Functional Imaging
• Expansion of Endocrine and Neuro-Oncology Referral Networks
• Fragmented Specialist Access and Reimbursement for Multimodal Care

Segment Analysis

Treatment held 64.31% of the Pituitary cancer market share in 2025 within the offering segmentation. Its position reflects sustained prescription revenue from somatostatin analogs, dopamine agonists, and cortisol-synthesis inhibitors. Surgery adds procedure-based revenue for eligible patients, while radiation therapy adds later demand for residual disease or cavernous sinus involvement. The treatment base has been built over decades around medicines with high annual cost per patient.

Diagnosis is forecast to grow at a 10.58% CAGR through 2031, faster than treatment. MRI upgrades, artificial intelligence-enhanced sequences, functional PET imaging, and molecular workups support this pace. Hormone and biochemical testing has a high order frequency because functioning tumors need continuing monitoring. Histopathology, immunohistochemistry, Ki-67 assessment, MGMT testing, and MMR status can add value as pre-treatment requirements become more routine. Vision and ophthalmic assessment remains necessary for surgical planning, while tailored contrast protocols can increase the value of diagnostic work. The Pituitary cancer industry is supported by services that link imaging to laboratory assessment, pathology, specialist review, and treatment planning.

Functioning pituitary adenoma accounted for 63.44% of the Pituitary cancer market share in 2025 within the cancer-type segmentation. Its scale is linked to its higher prevalence and the continuing pharmacotherapy needed to control hormone excess. Prolactinomas account for 40% of all pituitary tumors. Acromegaly-related adenomas have a lower prevalence but can create higher revenue per patient because long-term somatostatin analogs or GH-receptor antagonists may be required. Functioning tumors therefore generate repeat activity across drug therapy, endocrine testing, and specialist follow-up.

Non-functioning pituitary adenoma generates much of its revenue through surgery and follow-up imaging, while the absence of a hormone-directed therapy leaves an unmet need. Pituitary carcinoma is forecast to grow at a 10.52% CAGR through 2031, reflecting high management costs and limited treatment choices rather than large patient numbers. Published case material on 177Lu-DOTATATE for SSTR-positive metastatic PitNETs indicates a defined high-cost treatment setting. The move from pituitary adenoma to PitNET, formalized in a 2025 Japanese guideline update, can bring borderline-aggressive cases into more intensive protocols. Growth in the carcinoma category can therefore partly reflect reclassification rather than new disease incidence. The Pituitary cancer industry needs to distinguish this coding effect from underlying demand growth.

Complete Report Scope:

• By Offering
  • Diagnosis
    • Magnetic Resonance Imaging
    • Computed Tomography
    • Positron Emission Tomography and Molecular Imaging
    • Hormone and Biochemical Testing
    • Vision and Ophthalmic Testing
    • Histopathology and Immunohistochemistry
    • Molecular and Genetic Testing
  • Treatment
    • Surgery
    • Radiation Therapy
    • Medications
    • Peptide Receptor Radionuclide Therapy
    • Active Surveillance and Supportive Care
• By Cancer Type
  • Functioning Pituitary Adenoma
  • Non-Functioning Pituitary Adenoma
  • Pituitary Carcinoma
• By Age Group
  • Pediatric
  • Adult
  • Older Adult
• By End User
  • Hospitals
  • Specialty Clinics
  • Cancer Treatment Centers
  • Ambulatory Surgical Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.61% of revenue in 2025, the largest geographic contribution to the Pituitary cancer market. The United States has a dense network of academic pituitary programs, high drug spending for acromegaly and Cushing disease, and active drug development. FDA approval of paltusotine in September 2025 added an oral option for adults with acromegaly. The treatment is relevant for patients with inadequate control on injectable somatostatin analogs and those seeking an alternative to monthly injections. Existing diagnosed patients can therefore enter more intensive or more convenient treatment sequences.

Asia-Pacific is forecast to grow at a 10.85% CAGR through 2031, the fastest regional rate in the Pituitary cancer market. Japan has established pituitary surgery infrastructure and is adopting more advanced endoscopic approaches, while China is expanding tertiary hospitals that can identify previously undiagnosed tumors. India and South Korea are developing dedicated neurosurgery and endocrinology programs. The Middle East and Africa and South America remain early-stage areas, with elite care concentrated in major urban academic hospitals and underdiagnosis outside them. Referral network expansion is likely to have a greater effect than new technology alone in improving access.

List of Companies Covered in this Report:

• Accuray
• Amgen
• AstraZeneca
• Bayer
• Camurus AB
• Corcept Therapeutics Incorporated
• Crinetics Pharmaceuticals, Inc.
• Debiopharm International SA
• Elekta
• Eli Lilly and Company
• Roche
• Ion Beam Applications SA
• Ipsen
• Merck
• Novartis
• Pfizer
• RaySearch Laboratories
• Recordati S.p.A.
• Siemens Healthineers
• Takeda Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support